The safety and efficacy of Cyberknife® for thymic malignancy

Cancer Radiother. 2021 Apr;25(2):119-125. doi: 10.1016/j.canrad.2020.06.026. Epub 2021 Mar 3.


Purpose: To evaluate the safety and efficacy of Cyberknife® (CK) for the treatment of primary or recurring thymic tumours.

Materials and methods: We retrospectively reviewed 12 patients (16 tumour lesions) with primary or recurring thymic tumours who were treated with CK between March 2008 and October 2017. Their data was stored in prospectively collected database. Kaplan-Meier method was used to calculate survival curves.

Results: Five patients (41.7%), who had inoperable disease or refused surgery, were treated with CK initially, and 7 patients (58.3%) were treated with CK when they had recurrence diseases. The disease sites treated with CK were primary tumour site (5), regional lymph nodes (4), tumour bed (3), chest wall (2), pleura (1), and bone (1). The median target volume was 43.8 cm3 (range, 13.1-302.5cm3) for the 16 tumour lesions. The median follow-up time was 69.3 months (range, 9.7-124.8 months). The median survival time was 48.2 months, and the 5-year and 10-year OS rates were 68.2% and 45.5%, respectively. A high response rate for the tumour lesions irradiated with CK was obtained. Only one patient (8%) experienced in-field recurrence, and the 5-year local recurrence free survival was 90.9%. A case indicated that CK may induce the abscopal effect, which provides the potential to combine CK and immunotherapy. No severe radiation related toxicities were observed, and no treatment related death occurred.

Conclusion: CK treatment resulted in good outcomes, particularly local control, with minimal side effects, in highly selected patients with primary and recurring thymic tumours. More studies with larger sample are needed.

Keywords: Cyberknife; Efficacité; Efficacy; Safety; Sécurité; Thymic malignancy; Tumeur maligne thymique.

MeSH terms

  • Adult
  • Aged
  • Female
  • Follow-Up Studies
  • Humans
  • Kaplan-Meier Estimate
  • Lung Neoplasms / radiotherapy
  • Lung Neoplasms / secondary
  • Lymphatic Irradiation
  • Male
  • Mediastinal Neoplasms / radiotherapy
  • Mediastinal Neoplasms / secondary
  • Middle Aged
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / radiotherapy*
  • Radiosurgery / adverse effects
  • Radiosurgery / methods*
  • Radiotherapy, Image-Guided / adverse effects
  • Radiotherapy, Image-Guided / methods*
  • Retrospective Studies
  • Robotic Surgical Procedures / adverse effects
  • Robotic Surgical Procedures / methods*
  • Safety
  • Survival Rate
  • Thymoma / mortality
  • Thymoma / pathology
  • Thymoma / radiotherapy*
  • Thymoma / secondary
  • Thymus Neoplasms / mortality
  • Thymus Neoplasms / pathology
  • Thymus Neoplasms / radiotherapy*
  • Time Factors